TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20525328

Group type: EXPERIMENTAL
Intervention: Improved hand hygiene with guided hand-washing with soap and water
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Improved hand hygiene with alcohol-based hand rubbing disinfectant
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Control arm (no change in hand hygiene practices)
Number of subjects: 1050
Study: 18401652

Group type: EXPERIMENTAL
Intervention: Verbal explanation alone (group A)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Verbal explanation with request to sign a form (group B)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Staff members
Number of subjects: 37
Study: 16796223

Group type: EXPERIMENTAL
Intervention: Modafinil, 400 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Caffeine, 600 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine, 20 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 14671195

Group type: EXPERIMENTAL
Intervention: 25 mg exemestane daily for 10 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg exemestane daily for 10 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25 mg exemestane (PK study)
Number of subjects: 12
Study: 11261810

Group type: EXPERIMENTAL
Intervention: Low-dose prednisone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 8792690

Group type: EXPERIMENTAL
Intervention: 10 MU of interferon-alpha 2b (IFN-alpha), three times weekly for 6 months (group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 3 MU of interferon-alpha 2b (IFN-alpha), three times weekly for 6 months (group B)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 10 MU of interferon-alpha 2b (IFN-alpha) (group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 3 MU of interferon-alpha 2b (IFN-alpha) (group B)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Advanced histological stage (severe fibrosis and cirrhosis)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Presence of genotype 1
Number of subjects: 58
Study: 7963722

Group type: EXPERIMENTAL
Intervention: Tetravalent live oral rhesus rotavirus vaccine (RRV‐TV)
Number of subjects: 26
Study: 3627885

Group type: EXPERIMENTAL
Intervention: Fee-for-service reimbursement
Number of subjects: 2
Study: 28586534

Group type: EXPERIMENTAL
Intervention: tele‐IPT plus standard care
Number of subjects: 147

Group type: COMPARATOR
Intervention: working alliance
Number of subjects: 147

Group type: COMPARATOR
Intervention: goal and task working alliance subscales
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: tele‐IPT
Number of subjects: 147
Study: 27180442

Group type: EXPERIMENTAL
Intervention: Topical cream loaded with 2% Ananas comosus extract
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo control cream (no extract)
Number of subjects: 11
Study: 25113138

Group type: EXPERIMENTAL
Intervention: Intervention arm (n=10 practices)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control arm (n=10 practices)
Number of subjects: 20
Study: 21710113

Group type: EXPERIMENTAL
Intervention: Endoscopic excision
Number of subjects: 21

Group type: COMPARATOR
Intervention: Open excision
Number of subjects: 21
Study: 19284125

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (Voluven)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Lactated Ringer solution
Number of subjects: 29
Study: 17240222

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (800 microg)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 652
Study: 15876453

Group type: EXPERIMENTAL
Intervention: Triclosan-containing compomer (TC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 36% phosphoric acid (PH) for 15s
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (Control - CO)
Number of subjects: 30
Study: 12476540

Group type: EXPERIMENTAL
Intervention: Flunisolide HFA 85 micrograms
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Flunisolide HFA 170 micrograms
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Flunisolide HFA 340 micrograms
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Flunisolide HFA (all doses)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 6 beta‐OH flunisolide (inactive metabolite)
Number of subjects: 21
Study: 9596204

Group type: EXPERIMENTAL
Intervention: Teril 400 CR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tegretol CR Divitab
Number of subjects: 0
Study: 8169675

Group type: EXPERIMENTAL
Intervention: Intravenous rapid infusion of indomethacin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intravenous slow infusion of indomethacin
Number of subjects: 19
Study: 29120039

Group type: EXPERIMENTAL
Intervention: Prostin 15M 250 microg intramuscular injection every two hours until 1 cm cervical dilation, then every three hours until abortion.
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Prophylactic loperamide and emidoxyn given in 53 cases.
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Blood loss measured by alkaline hematin method in 50 cases.
Number of subjects: 322
Study: 30145595

Group type: EXPERIMENTAL
Intervention: ADL training
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Combined multicomponent exercise and ADL training
Number of subjects: 87

Group type: COMPARATOR
Intervention: No physical stimulation
Number of subjects: 87
Study: 28148280

Group type: EXPERIMENTAL
Intervention: Adalimumab and methotrexate combination treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Adalimumab monotherapy
Number of subjects: 36
Study: 26036774

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) in patients with known OSA (66/94, 70%)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) in patients with high risk STOP-BANG scores (95/124, 77%)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) in patients with low risk OSA scores (29/32, 91%)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: High risk STOP-BANG score predicting recurrent AF in patients without prior OSA diagnosis
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Non-paroxysmal AF patients
Number of subjects: 247
Study: 24107880

Group type: EXPERIMENTAL
Intervention: Pantocalcin (hopantenic acid preparation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 21924414

Group type: EXPERIMENTAL
Intervention: Early-hCG group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Late-hCG group
Number of subjects: 120
Study: 19033842

Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal surgery simulator training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 15
Study: 16990670

Group type: EXPERIMENTAL
Intervention: Single reading with computer-aided detection (CAD)
Number of subjects: 10267

Group type: COMPARATOR
Intervention: Double reading
Number of subjects: 10267
Study: 14656361

Group type: EXPERIMENTAL
Intervention: Tartrazine (5 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: IgE tests for food allergy
Number of subjects: 102
Study: 10759359

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg bid
Number of subjects: 490

Group type: COMPARATOR
Intervention: Penicillin V 50,000 IU given in three divided doses
Number of subjects: 490
Study: 8823889

Group type: EXPERIMENTAL
Intervention: Left ear (right hemisphere)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Right ear (left hemisphere)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both ears (combined hemispheres)
Number of subjects: 139
Study: 1295136

Group type: EXPERIMENTAL
Intervention: Amodiaquine therapy (25 mg base/kg over 3 days)
Number of subjects: 109
Study: 6203285

Group type: EXPERIMENTAL
Intervention: 10-butyryl dithranol (butantrone)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: dithranol, 10-propionyl dithranol, 10-butyryl dithranol
Number of subjects: 17
Study: 29308849

Group type: EXPERIMENTAL
Intervention: Overloaded 10‐second cycling PAP protocol followed by a Wingate Test at 10 minutes post-PAP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bestpeak‐P condition (peak power output)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control session (sub‐maximal cycling warm-up followed by a Wingate Test)
Number of subjects: 20
Study: 30209862

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27776079

Group type: EXPERIMENTAL
Intervention: Low level continuous heat (LLCH) wraps applied for 6 hours at home before home exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low level continuous heat (LLCH) wraps
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo ibuprofen
Number of subjects: 50
Study: 24916520

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 22280484

Group type: EXPERIMENTAL
Intervention: Patient education and multimodal physiotherapy (including neuromuscular training and home exercises)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Patient education (written information and general advice)
Number of subjects: 102
Study: 21198234

Group type: EXPERIMENTAL
Intervention: Transference work
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Transference work with lower therapeutic alliance ratings
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low dose of transference work
Number of subjects: 49
Study: 17413101

Group type: EXPERIMENTAL
Intervention: High Glycemic Load (HG) diet at 30% calorie restriction (CR)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (LG) diet at 30% calorie restriction (CR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: High Glycemic Load (HG) diet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low Glycemic Load (LG) diet
Number of subjects: 34
Study: 16234005

Group type: EXPERIMENTAL
Intervention: Wireless capsule endoscopy (WCE)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Enteroclysis
Number of subjects: 31
Study: 12140795

Group type: EXPERIMENTAL
Intervention: RC-Cornet(R) therapy group (combined-PEP therapy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Drug therapy group (theophylline, salmeterol, ipratropiumbromide, systemic steroids)
Number of subjects: 50
Study: 10430331

Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg/week, adjusted up to 22.5 mg/week
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Methotrexate and Placebo
Number of subjects: 33
Study: 7563988

Group type: EXPERIMENTAL
Intervention: Overt task‐oriented verbalization
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Covert task‐oriented verbalization
Number of subjects: 120

Group type: COMPARATOR
Intervention: No verbalization
Number of subjects: 120
Study: 2250563

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (CT) 100 UI administered by intravenous route
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (CT) 100 UI administered by intramuscular route
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (CT) 100 UI administered by nasal route
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7282732

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg every 6 hours and 80 mg every 6 hours)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-dose Verapamil (120 mg every 6 hours)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol and High-dose Verapamil
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 18
Study: 31596127

Group type: EXPERIMENTAL
Intervention: Artificial pancreas with learning algorithm (daily updates of basal rates and carbohydrate ratios)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Artificial pancreas alone (no learning algorithm)
Number of subjects: 34
Study: 30836685

Group type: EXPERIMENTAL
Intervention: High-frequency + self-selected timing (HST)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Low-frequency + self-selected timing (LST)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-frequency + assigned timing (HAT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Low-frequency + assigned timing (LAT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 28385473

Group type: EXPERIMENTAL
Intervention: Positive 6-day culture
Number of subjects: 299

Group type: COMPARATOR
Intervention: Negative 6-day culture
Number of subjects: 299
Study: 25885862

Group type: EXPERIMENTAL
Intervention: SMS reminders at 6, 10, and 14 weeks in addition to routine health education
Number of subjects: 304

Group type: COMPARATOR
Intervention: Routine health education without SMS reminders
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 304
Study: 24081011

Group type: EXPERIMENTAL
Intervention: Test of Infant Motor Performance (TIMP)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Bayley Motor scale
Number of subjects: 145
Study: 21493943

Group type: EXPERIMENTAL
Intervention: Comprehensive support including fees, uniforms, and a school-based helper
Number of subjects: 329
Study: 19781466

Group type: EXPERIMENTAL
Intervention: Torsional ultrasound mode
Number of subjects: 400

Group type: COMPARATOR
Intervention: Longitudinal ultrasound mode
Number of subjects: 400
Study: 16440428

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-PEG group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (ventilated patients without reflux)
Number of subjects: 36
Study: 15497780

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10778882

Group type: EXPERIMENTAL
Intervention: Test diet with soy protein foods (33 g/d soy protein)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Test diet with soy protein foods
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 31
Study: 9068332

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 80
Study: 7870896

Group type: EXPERIMENTAL
Intervention: Desipramine (75 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isoproterenol infusion
Number of subjects: 14
Study: 3530865

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at bedtime for 6 months)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Ranitidine (open treatment)
Number of subjects: 108
Study: 30940400

Group type: EXPERIMENTAL
Intervention: Smartphone monitoring with CrossCheck behavioral sensing system
Number of subjects: 61
Study: 29177440

Group type: EXPERIMENTAL
Intervention: 1 year of adjuvant sorafenib
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 3 years of adjuvant sorafenib
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo (no adjuvant therapy)
Number of subjects: 233
Study: 26308112

Group type: EXPERIMENTAL
Intervention: Vaqta/Infanrix PedvaxHIB on Day‐1 and Vaqta at Week‐24
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infanrix PedvaxHIB on Day‐1, Vaqta at Week‐4, and Vaqta at Week‐28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaqta/PedvaxHIB on Day‐1 and Vaqta Week‐24
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PedvaxHIB on Day‐1, Vaqta at Week‐4, and Vaqta at Week‐28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaqta on Day‐1 and Vaqta at Week‐24 (safety only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Groups 1-4 (concomitant administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant administration of Vaqta, PedvaxHIB, and Infanrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant vs nonconcomitant groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant administration
Number of subjects: 0
Study: 25473191

Group type: EXPERIMENTAL
Intervention: Lubiprostone (Amitza), orally twice a day for six days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Senna (generic), two capsules daily for six days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Senna (generic)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both lubiprostone and Senna
Number of subjects: 64
Study: 22901344

Group type: EXPERIMENTAL
Intervention: Raise end-tidal P(CO₂) group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Lower end-tidal P(CO₂) group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 74
Study: 20848932

Group type: EXPERIMENTAL
Intervention: Osteoinduction active material (OAM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Autogenous ilium cancellous bone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: OAM
Number of subjects: 27
Study: 17957158

Group type: EXPERIMENTAL
Intervention: Orlistat treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15878095

Group type: EXPERIMENTAL
Intervention: 50 Gy in 25 fractions (F)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 F
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: 42.9 Gy in 13 F
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: 50 Gy in 25 F
Number of subjects: 1410
Study: 11952580

Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy (6 MIU intramuscularly every day for 2 weeks, then three times a week for 14 weeks and finally twice a week for 88 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 9605029

Group type: EXPERIMENTAL
Intervention: Intervention group (Group 2) received 2 books and educational materials.
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (Group 1) did not receive books or educational materials.
Number of subjects: 151
Study: 7698517

Group type: EXPERIMENTAL
Intervention: Glipizide (2.5 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 2744191

Group type: EXPERIMENTAL
Intervention: TDT catheter (Prodimed, Neuilly‐en‐Thelle, France)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: TDT catheter (Prodimed, Neuilly‐en‐Thelle, France) under ultrasound guidance
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Frydman catheter (Prodimed, Neuilly‐en‐Thelle, France)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Wallace catheter (H.G. Wallace Limited, Colchester, England)
Number of subjects: 400
Study: 792893

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentazocine hydrochloride
Number of subjects: 0
Study: 30833149

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) filler injection
Number of subjects: 72

Group type: COMPARATOR
Intervention: Polylactic Acid (PLA) filler injection
Number of subjects: 72
Study: 28286061

Group type: EXPERIMENTAL
Intervention: Adalimumab for 52 weeks
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo for 16 weeks followed by adalimumab for 52 weeks
Number of subjects: 107
Study: 25761731

Group type: EXPERIMENTAL
Intervention: Flow-limited group (FL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-flow-limited group (non-FL)
Number of subjects: 14
Study: 23305820

Group type: EXPERIMENTAL
Intervention: 12-step facilitation for stimulant abusers
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: BIS‐11 motor score
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: BIS‐11 non‐planning and total scores
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Stroop interference scores
Number of subjects: 182
Study: 21969930

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 250 mcg twice daily for four weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Open-label treatment with fluticasone propionate 250 mcg/salmeterol 50 mcg
Number of subjects: 12
Study: 18524134

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) solutions (light, medium, heavy molecular weight)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Addition of platelet activating factor IV (PAF IV)
Number of subjects: 29
Study: 16336479

Group type: EXPERIMENTAL
Intervention: Intradiscal thermal annuloplasty (IDTA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Radiofrequency annuloplasty (RFA)
Number of subjects: 42
Study: 12014900

Group type: EXPERIMENTAL
Intervention: HW with non-antiseptic soap for 10 seconds (US10)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HW with non-antiseptic soap for 30 seconds (US30)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HW with antiseptic soap for 10 seconds (AS10)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HW with antiseptic soap for 30 seconds (AS30)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HW with antiseptic soap for 60 seconds (AS60)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Alcohol-based handrub (ABH)
Number of subjects: 43

Group type: COMPARATOR
Intervention: HW with non-antiseptic soap (US)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pre-HH specimens
Number of subjects: 43
Study: 10443327

Group type: EXPERIMENTAL
Intervention: Regular insulin injected 5 minutes before meals
Number of subjects: 15

Group type: COMPARATOR
Intervention: Regular insulin injected 30 minutes before meals
Number of subjects: 15
Study: 7797697

Group type: EXPERIMENTAL
Intervention: Collaborative research utilization model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no participation in the model)
Number of subjects: 0